Cytokinetics Presents New Data in Patients With
Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and...
Source: globenewswire.com
Dosing With News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dosing With. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dosing With Today - Breaking & Trending Today
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical... | May 20, 2023
Source: marketscreener.com
Cytokinetics Presents Positive Results From Cohort 4 of
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive...
Source: globenewswire.com
Cytokinetics Presents New Data From REDWOOD-HCM OLE in
Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows...
Source: globenewswire.com
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late
New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten ...
Source: globenewswire.com